We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
TAL
26
TIG Advisors LLC
New York
– -$140M -1,057,892 Closed
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
– -$123M -931,330 Closed
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
– -$122M -923,809 Closed
Charles Schwab
29
Charles Schwab
California
– -$118M -895,664 Closed
LP
30
LMR Partners
United Kingdom
– -$114M -863,134 Closed
Millennium Management
31
Millennium Management
New York
– -$111M -844,073 Closed
PA
32
Perceptive Advisors
New York
– -$104M -786,358 Closed
JP Morgan Chase
33
JP Morgan Chase
New York
– -$100M -759,991 Closed
KC
34
Kryger Capital
United Kingdom
– -$99M -750,571 Closed
FTCM
35
First Trust Capital Management
Illinois
– -$94.9M -719,552 Closed
AAM
36
Alpine Associates Management
Florida
– -$94.9M -719,500 Closed
SCM
37
Suvretta Capital Management
New York
– -$92.5M -700,904 Closed
Deutsche Bank
38
Deutsche Bank
Germany
– -$91.5M -693,427 Closed
NAM
39
Nexpoint Asset Management
Texas
– -$91.2M -691,280 Closed
First Trust Advisors
40
First Trust Advisors
Illinois
– -$87.6M -663,916 Closed
Northern Trust
41
Northern Trust
Illinois
– -$83.7M -634,535 Closed
ACA
42
Avoro Capital Advisors
New York
– -$82.5M -625,000 Closed
Tudor Investment Corp
43
Tudor Investment Corp
Connecticut
– -$82M -621,815 Closed
Renaissance Technologies
44
Renaissance Technologies
New York
– -$81.9M -621,200 Closed
Man Group
45
Man Group
United Kingdom
– -$81.9M -620,699 Closed
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
– -$80.1M -606,808 Closed
Fidelity International
47
Fidelity International
Bermuda
– -$74.9M -568,000 Closed
Amundi
48
Amundi
France
– -$74M -561,266 Closed
BCM
49
Beryl Capital Management
California
– -$71.5M -541,642 Closed
RAM
50
Readystate Asset Management
Illinois
– -$66.9M -507,200 Closed
1
2
3 4 5

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.